References
- European Heart Rhythm Association and the Heart Rhythm Society, Fusten V, Ryden LE, Cannon DS, et al. ACC/AHA/ ESC 2006 Guidelines for the management of patients with atrial fibrillation – Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006;114:700–52
- Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540–6
- Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost 2006;4:1180–5
- Bushnell CD, Matchar DB. Pharmacoeconomics of atrial fibrillation and stroke prevention. Am J Managed Care 2004;10:S66–71
- Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006;96:274–84
- Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3–19
- O’Brien CL, Gage BF. Costs and effectiveness of ximiligatran for stroke prophylaxis in chronic atrial fibrillation. J Am Med Assoc 2005;293:699–706
- Hillinen T, Martikainen JA, Soini EJO, et al. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006;22:683–92
- Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal anticoagulation. Am J Managed Care 2004;10:S451–8
- Go AS, Hylek EM, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–26
- Hylek EM, Go AS, Chang Y, et al. Anticoagulation therapy for stroke precaution in atrial fibrillation: how well do randomized trails translate into clinical practice? J Am Med Assoc 2003;290:2685–92
- Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 2006;166: 853–9
- Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation study. Ann Intern Med 1999;131:927–34
- Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. J Am Med Assoc 1995;274: 1839–45
- Hart AC, Schmidt K. 2004 DRG Expert 20th Edition. Ingenix, St. Anthony Publishing, Salt Lake City, UT 2004
- Wasserman Y. Physicians’ Fee Reference 2004. 21st Edition, Yale Wasserman Medical Publishers, Milwaukee, Wisconsin, 2004
- Bodenheimer TS, Grumback K. Understanding Health Policy: A Clinical Approach, 3rd edn. New York, NY: Lange Medical Books/McGraw-Hill, 2002
- 2003 Drug Topics Red Book 10th edn. Montvale, NJ: Thompson PDR, 2003
- Samsa GP, Matchar DB, Phillips DL, et al. Which approach to anticoagulation management is best?: Illustration of an interactive mathematical model to support informed decision making. J Thromb Thrombolysis 2002;14:103–11
- Lafata JE, Martin SA, Kaatz S, et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis. J Thromb Thrombolysis 2000;Suppl 1:S13–19
- Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31–7
- Seto TB, Taira DA, Tsevat J, et al. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997;29:122–30
- Gianetti J, Gensini G, De Caterina R. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy – equivalence of costs as a possible case for oral anticoagulants. Thromosis Haemostasis 1998;80:887–93
- Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998;29:1827–32
- Marchetti M, Pistorio A, Barone M, et al. Low molecular weight heparin versus warfarin for secondary prophylaxis of venousthromboembolism: a cost-effectiveness analysis. Am J Med 2001;111:130–9
- Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996;276:1172–7